CA2394167A1 - Compositions and methods for inhibiting endothelial cell proliferation - Google Patents

Compositions and methods for inhibiting endothelial cell proliferation Download PDF

Info

Publication number
CA2394167A1
CA2394167A1 CA002394167A CA2394167A CA2394167A1 CA 2394167 A1 CA2394167 A1 CA 2394167A1 CA 002394167 A CA002394167 A CA 002394167A CA 2394167 A CA2394167 A CA 2394167A CA 2394167 A1 CA2394167 A1 CA 2394167A1
Authority
CA
Canada
Prior art keywords
hgf
angiogenesis
fragments
cells
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002394167A
Other languages
English (en)
French (fr)
Inventor
Hong Liang
Kim Lee Sim
Clara Dey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Casi Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2394167A1 publication Critical patent/CA2394167A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002394167A 1999-12-15 2000-12-15 Compositions and methods for inhibiting endothelial cell proliferation Abandoned CA2394167A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17100799P 1999-12-15 1999-12-15
US60/171,007 1999-12-15
US19356600P 2000-03-31 2000-03-31
US60/193,566 2000-03-31
PCT/US2000/034039 WO2001044294A2 (en) 1999-12-15 2000-12-15 Compositions and methods for inhibiting endothelial cell proliferation

Publications (1)

Publication Number Publication Date
CA2394167A1 true CA2394167A1 (en) 2001-06-21

Family

ID=26866643

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002394167A Abandoned CA2394167A1 (en) 1999-12-15 2000-12-15 Compositions and methods for inhibiting endothelial cell proliferation

Country Status (5)

Country Link
EP (1) EP1242451A2 (ja)
JP (1) JP2003517007A (ja)
AU (1) AU784359B2 (ja)
CA (1) CA2394167A1 (ja)
WO (1) WO2001044294A2 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1320384B1 (en) * 2000-08-28 2007-10-10 Damavand Wound AB The synergetic effects of hgf and antibacterial treatment
CA2421251A1 (en) 2000-09-05 2002-03-14 Karolinska Innovations Ab Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen
US20070225218A1 (en) * 2001-06-29 2007-09-27 Delegeane Angelo M Extracellular Messengers
FR2831540B1 (fr) * 2001-10-31 2004-07-09 Inst Vaisseaux Et Du Sang Peptide isole du facteur de croissance hepatocytaire et ses variants, procede de preparation et utilisation en therapeutique en tant qu'agents antiangiogeniques
WO2004019991A2 (en) * 2002-08-30 2004-03-11 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
JP2004123650A (ja) * 2002-10-04 2004-04-22 Medgel Corp Ｎｋ４を含有する徐放性製剤
US20070224703A1 (en) * 2003-09-29 2007-09-27 Fariba Nayeri Rapid Determination of Hepatocyte Growth Factor (Hgf) in the Body Fluids
CN101189023B (zh) * 2005-03-31 2013-01-30 通用医疗公司 监测和调制hgf/hgfr活性
US8133867B2 (en) * 2006-03-20 2012-03-13 Seikagaku Corporation Method for treating rheumatoid arthritis with an antibody that binds to a hepatocyte growth factor receptor
WO2008099829A1 (ja) * 2007-02-14 2008-08-21 Japan Science And Technology Agency 実験動物の腸管癒着を形成する方法、腸管癒着実験動物の製造方法、腸管癒着抑制剤のスクリーニング方法及び腸管癒着抑制剤
JP2009091339A (ja) * 2007-10-12 2009-04-30 Seikagaku Kogyo Co Ltd 関節リウマチの処置剤
CN102336812B (zh) * 2010-07-28 2015-12-02 上海市第一人民医院 一种具有抑制血管生成活性的多肽

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0571387B1 (en) * 1990-09-14 2003-12-17 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce A non-mitogenic competitive hgf antagonist
JP3832674B2 (ja) * 1995-10-24 2006-10-11 敏一 中村 抗癌剤
NZ330537A (en) * 1995-12-13 2001-06-29 Childrens Medical Center Kringle 5 rerion of plasminogen as an endothelial cell proliferation inhibitor
US5801146A (en) * 1996-05-03 1998-09-01 Abbott Laboratories Compound and method for inhibiting angiogenesis
US6107473A (en) * 1997-10-01 2000-08-22 Smithkline Beecham Corporation Kringle-related clone HTHBZ47
GB9815505D0 (en) * 1998-07-16 1998-09-16 Adprotech Plc Polypeptide derivatives
JP2002535372A (ja) * 1999-01-28 2002-10-22 ザ チルドレンズ メディカル センター コーポレイション プラスミノーゲンクリングル４領域フラグメントおよび利用法
WO2000061179A1 (en) * 1999-04-14 2000-10-19 Karolinska Innovations Ab Kringle domains of plasminogen, capable of modulating angiogenesis in vivo

Also Published As

Publication number Publication date
AU3074801A (en) 2001-06-25
AU784359B2 (en) 2006-03-16
JP2003517007A (ja) 2003-05-20
EP1242451A2 (en) 2002-09-25
WO2001044294A3 (en) 2002-02-07
WO2001044294A2 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
US6544947B2 (en) Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
KR100336452B1 (ko) 앤지오스타틴및맥관형성억제를위한이의사용방법
US7485439B2 (en) Nucleic acids encoding plasminogen fragments and methods of use
US7329642B2 (en) β-2-glycoprotein is an inhibitor of angiogenesis
AU784359B2 (en) Compositions and methods for inhibiting endothelial cell proliferation
US6498144B1 (en) Use of scatter factor to enhance angiogenesis
JP2001518304A (ja) アンギオスタチン成分を含む融合タンパク質及び抗腫瘍療法におけるその使用
CA2240296C (en) Endothelial cell proliferation inhibitor and method of use
US20040253226A1 (en) Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using serine proteases
US20040121945A1 (en) Compositions and methods for inhibiting endothelial cell proliferation
Ikeda et al. Localization of thrombomodulin in the anterior segment of the human eye
CA2360690A1 (en) Plasminogen kringle 4 region fragments and methods of use
US7241446B2 (en) Methods for modulating angiogenesis via VEGF
CA2361334C (en) Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use
EP1268798B1 (en) Anti-angiogenic properties of vascostatin and fragments or variants thereof
EP0504291A4 (en) Novel proteins with oncostatin m activity and process for their preparation
US7629146B2 (en) Truncated 24kDa basic fibroblast growth factor
AU2001287274B2 (en) Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains
KR19990008029A (ko) 안기오스타틴 단편과 안기오스타틴 응집체 및 이의 이용방법
AU2001287274A1 (en) Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains

Legal Events

Date Code Title Description
FZDC Correction of dead application (reinstatement)
EEER Examination request
FZDE Dead